News

The study was initiated in December 2007 and these results from the blinded study are expected in the fourth quarter of 2008. There are two pivotal PSD502 studies

The acquisition of MicroCal will allow GE Healthcare to expand its offering of technologies for the rapidly growing areas of protein science and drug discovery research, said GE.

The study is being conducted at University of California, Los Angeles by Martina Wiedau-Pazos and is designed to evaluate the safety and efficacy of AEOL 10150 in an

This trial is designed to test the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly. The implant utilizes the company’s patented Hydron polymer technology

Each unit consists of one common share and one-half of one common share purchase warrant, with each whole common share purchase warrant entitling the holder to purchase one

Mr Fernandez has 12 years experience in the medical field. He has run three pulmonary rehab clinics in the Houston area and for the past six years has

The financing was led by Three Arch Partners and joined by additional new investors InterWest Partners and Pinnacle Ventures. Existing investors Charter Life Sciences, Great Point Partners, Versant

Takeda is the originator of the thiazolidinedione (TZD) class of oral anti-diabetic medications. Actos is a member of TZDs that help reduce insulin resistance, which is one of

Alogliptin is a dipeptidyl peptidase-IV inhibitor taken once a day, and was created by Takeda San Diego, Takeda’s wholly-owned subsidiary located in San Diego, California. Large-scale clinical studies